Vaccine Adjuvants Market Overview
The vaccine adjuvants market is estimated to be worth $4.3 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 2.7% during the forecast period. As per recent estimates (reported in May 2022), more than 11.6 billion doses of COVID-19 vaccines have been administered across 184 countries; this value roughly translates to 20.9 million doses per day. Vaccines have enabled the prevention of more than 37 million deaths due to various disease indications, such as cholera, diphtheria, influenza, tetanus, whooping cough and measles, between 2000 to 2019. Given the rate at which the global population is growing and taking into consideration the prevalent (such as the COVID-19 pandemic) and anticipated future trends, the demand for vaccines is likely to increase significantly. According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. In this regard, significant strides have been made to develop safe and effective, next generation vaccine candidates, such as sub-unit vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines. However, such vaccines employ purified non-living vaccine antigens (unlike their counterparts, live attenuated and inactivated vaccines) and are, most often, less immunogenic and require an additional aid to increase their immunogenicity against the target antigens. As a result, a variety of vaccine adjuvants (substances with the innate potential to augment an immune response), such as AS04 (Cervarix®), MF59 (Fluad®), AS01B (Shingrix®) and CpG 1018 (Heplisav-B®), have been discovered and are now available for the development of more effective and versatile vaccine formulations. It is worth highlighting that aluminum hydroxide containing adjuvants have been used in vaccines since the 1930s. Additionally, MF59, an oil-in-water emulsion, is the adjuvant in flu vaccine (licensed for use in pandemic and seasonal influenza vaccines in many countries).
Presently, an increasing number of vaccines under development are incorporating adjuvants in vaccines owing to various advantages offered by such agents, including improved adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each specific pathogen and facilitation of the use of smaller doses of antigen. Further, majority of the adjuvants in vaccines enhance humoral immunity; however, several novel adjuvants in clinical or preclinical development are focused on enhancing specific types of T-cell responses to generate multifaceted immune responses required for complex indications, such as malaria and HIV-AIDS. Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of adjuvants in vaccines. It is worth highlighting that capital investments worth over USD 5.5 billion have been made by various private and public sector investors during the last five years to fund the product development activity in vaccine adjuvants market. In addition, there have been several recently reported instances of collaborations between industry / academic stakeholders to advance the development of various adjuvants. Driven by the increasing demand for safe and effective vaccines, ongoing pace of innovation in this field and financial support from the investors, the vaccine adjuvants market is likely to witness substantial market growth during the forecast period.
Key Companies in Vaccine Adjuvants Market
Examples of key companies engaged in vaccine adjuvants market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Adjuvance Technologies, Avanti Polar Lipids, Blue Willow Biologics, Novavax, Phibro Animal Health and Vaxart. This market report includes an easily searchable excel database of all the companies providing vaccine adjuvants, worldwide.
Recent Developments in Vaccine Adjuvants Market:
Several recent developments have taken place in the field of vaccine adjuvants. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In August 2023, GSK announced the FDA approval of Arexvy, a respiratory syncytial virus vaccine, adjuvanted for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) for the individuals 60 years of age and older.
- In June 2023, Novavax collaborated with Gates Foundation Offshoot to develop malaria and TB shots. Additionally, Gates Foundation aims to utilize Novavax’s vaccine adjuvant Matrix-M in preclinical research.
- In May 2023, Croda entered into a strategic partnership with Botanical Solution in order to accelerate production of sustainable vaccine adjuvant QS-21.
Scope of the Report
The ‘Vaccine Adjuvants Market – Distribution by Type of Vaccine Adjuvant (Aluminum Salts, Oil-based Emulsions, Bacterial Compounds, Lipids, Nucleic Acids and Others), Route of Administration (Intramuscular, Subcutaneous, Oral, Intravenous and Others), Target Therapeutic Area (Infectious Diseases, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA and RoW): Industry Trends and Global Forecasts, 2022-2035’ market report features an extensive study of the current market landscape, market size, market forecast and future opportunities of the vaccine adjuvant market. The market research report features an in-depth analysis, highlighting the capabilities of vaccine adjuvant developers.
Amongst other elements, the market report features:
- A detailed overview of the overall landscape of vaccine adjuvant developers, along with information on several relevant parameters, such as their year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific and rest of the world), type of vaccine adjuvant (based on composition (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), based on chemical structure (inorganic adjuvants and organic adjuvants), based on function (humoral immunity activator, cell-mediated immunity activator and others)), phase of development (preclinical, clinical, commercial, and undisclosed), type of product (combinational adjuvants and individual adjuvants), type of molecular target (toll-like receptors, CD4 + T cells, and others), route of administration (intramuscular, subcutaneous, intranasal, intravenous, intraperitoneal, intradermal, oral and sublingual), target therapeutic area (infectious diseases, oncological disorders, immunological disorders, and dermatological disorders), type of compatible vaccine (Sub-unit, Inactivated, DNA / RNA, conjugate, live-attenuated, toxoid and others) and application area (human vaccine adjuvants, veterinary vaccine adjuvants and research vaccine adjuvants).
- An insightful competitiveness analysis of vaccine adjuvant developers, based on supplier power (in terms of years of experience), company competitiveness (type of vaccine adjuvant (based on composition, chemical structure, function), type of product, type of molecular target, phase of development, type of compatible vaccine, route of administration, type of therapeutic area and application area) and number of vaccine adjuvants developed.
- Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in vaccine adjuvants market. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to vaccine adjuvant portfolio, recent developments, and an informed future outlook.
- A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
- An in-depth analysis of patents related to vaccine adjuvants, filed / granted since 2017, based on several relevant parameters, such as patent type, application year, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
- An in-depth analysis of around 50 vaccine developers that are likely to partner with vaccine adjuvant developers, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of vaccines in pipeline and their stage of development) and type of vaccine.
- An analysis of recent partnerships inked between stakeholders engaged in vaccine adjuvants market, during the period 2018-2022 (till February), covering acquisitions, commercialization agreements, joint ventures, licensing agreements, manufacturing agreements, material transfer agreements, mergers, product development agreements, research development agreements, service agreements, service alliances and supply agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, type of vaccine adjuvant, type of product and most active players (on the basis of number of partnerships). It also highlights the regional distribution of the partnership activity in this market.
- A detailed analysis of various investments received by players engaged in vaccine adjuvants market, during the period 2018-2022 (till February), based on several relevant parameters, such as year of investment, number of funding instances, amount invested, type of funding (grant, seed, venture capital, initial public offering, secondary offering, other equity, and debt) and type of investor, along with information on the most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and geographical distribution (in terms of number of funding instances and amount invested).
- A case study presenting the USFDA approved vaccines, along with the information on their year of approval, type of vaccine, type of vaccine adjuvant and target therapeutic area.
One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity associated with the vaccine adjuvant market, over the coming 13 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as [A] type of vaccine adjuvant (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), [B] route of administration (intramuscular, subcutaneous, oral, intravenous, and others), [C] target therapeutic area (infectious diseases, oncological disorders, and others), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market research report were also influenced by discussions held with senior stakeholders in the industry. The market report features detailed transcripts of interviews held with the following individuals:
- Co-founder, Scientific Referent, Very Small Company, France
- Chief Executive Officer, Very Small Company, Germany
- Director of Business Development, Very Small Company, US
Frequently Asked Questions
Question 1: What are adjuvants? Answer:
Vaccine adjuvants are a class of chemical compounds with the innate potential to augment an immune response. These compounds are primarily utilized for the development of more effective and versatile vaccine formulations.
Question 2: How big is the vaccine adjuvants market? Answer:
The vaccine adjuvants market size is estimated to be worth $4.3 billion in 2022.
Question 3: What is the projected market growth of the vaccine adjuvants market? Answer:
The vaccine adjuvants market is expected to grow at compounded annual growth rate (CAGR) of 2.7% during the forecast period 2022 - 2035.
Question 4: Who are the leading companies in the vaccine adjuvants market? Answer:
Examples of key companies engaged in vaccine adjuvants market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Adjuvance Technologies, Avanti Polar Lipids, Blue Willow Biologics, Novavax, Phibro Animal Health and Vaxart.
Question 5: How many companies are currently engaged in the vaccine adjuvants market? Answer:
Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants.
Question 6: How much money has been invested in the vaccine adjuvants market over the last few years? Answer:
Capital investments worth over USD 5.5 billion have been made by various private and public sector investors during the last five years to fund the product development activity in the vaccine adjuvants market.
Question 7: Which region is the hub for companies engaged in the vaccine adjuvants market? Answer:
North America emerged as the hub for companies engaged in the vaccine adjuvants market, with over 50% of the companies established in the region.